Both infigratinib (BGJ398) and pemigatinib are orally bioavailable FGFR1-3 specific inhibitors that are approved as second-line treatment for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 dysregulation. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.